Nectar Lifesciences Board of Directors

Get the latest insights into the leadership at Nectar Lifesciences. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Sanjiv Goyal Chairman & Managing Director
Mr. Puneet Sud Director - Operations
Dr. Indu Pal Kaur Independent Director
Mr. Ajay Swaroop Independent Director
Dr. Rupinder Tewari Independent Director
Dr. Kuldip Kumar Bhasin Independent Director
Ms. Meena Verma Nominee Director

Nectar Lifesciences Share price

NECLIFE

14.66

0.16 (1.10%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:31 IST
BUYSELL
Today's High

14.95

Today's Low

13.90

52 Week Low

13.05

52 Week High

56.50

The current prices are delayed, login to your account for live prices

Nectar Lifesciences FAQs

The board at Nectar Lifesciences consists of experienced professionals, including Mr. Sanjiv Goyal , Mr. Puneet Sud , and others, overseeing the company’s strategic and corporate governance.

Directors at Nectar Lifesciences are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Sanjiv Goyal is the current chairman at Nectar Lifesciences.

Executive directors at Nectar Lifesciences are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Nectar Lifesciences adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Nectar Lifesciences, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.